SNO4 Antibody

What is SOX4 and why is it an important research target?

SOX4 functions as a critical transcription factor that regulates gene expression during development, particularly in the differentiation of various cell types. This protein binds to specific DNA sequences, influencing target gene transcription involved in cell fate determination and essential developmental processes across multiple tissues and organs. SOX4's ability to modulate these pathways is vital for proper embryonic development and tissue homeostasis, with its dysregulation implicated in several human diseases including certain cancers and developmental disorders. Its conservation throughout evolution underscores SOX4's fundamental importance in developmental biology, making it a significant target for both basic and applied sciences . Research involving SOX4 antibodies allows investigators to elucidate the complex signaling pathways and developmental programs in which this transcription factor participates, providing insights into both normal physiology and pathological states.

What applications are SOX4 antibodies validated for in research settings?

SOX4 antibodies have been extensively validated for multiple research applications with specific optimization parameters for each technique. For immunocytochemistry and immunofluorescence applications, commercially available SOX4 antibodies typically perform optimally at concentrations ranging from 2-10 μg/ml, with fixation protocols commonly employing paraformaldehyde followed by Triton X-100 permeabilization . In immunohistochemistry applications, including paraffin-embedded tissues, dilutions between 1:1000 and 1:2500 are typically recommended, with heat-induced epitope retrieval (HIER) at pH 6.0 often producing optimal results . Western blotting, immunoprecipitation, and enzyme-linked immunosorbent assays (ELISA) are additional validated applications with specific SOX4 antibodies like the B-7 clone demonstrating consistent performance across mouse, rat, and human samples . The nuclear localization of SOX4 makes it particularly suitable for studying transcription factor dynamics using techniques that preserve nuclear architecture during sample preparation.

How should SOX4 antibodies be stored and handled to maintain reactivity?

Proper storage and handling of SOX4 antibodies is critical for maintaining their specificity and reactivity over time. For short-term storage, commercially available SOX4 antibodies should be maintained at 4°C, while long-term storage requires aliquoting and freezing at -20°C to minimize freeze-thaw cycles that can degrade antibody quality . Most commercial preparations are formulated in phosphate-buffered saline (PBS) at pH 7.2 with substantial glycerol content (approximately 40%) to prevent freeze damage, and many contain 0.02% sodium azide as a preservative to inhibit microbial growth . When working with SOX4 antibodies, it's advisable to centrifuge the product briefly before opening to collect the solution at the bottom of the vial and to handle the antibody using sterile technique to prevent contamination. Repeated freeze-thaw cycles should be strictly avoided as they can lead to antibody denaturation, aggregation, and loss of binding capacity, making it essential to prepare appropriate working aliquots before freezing the stock solution for long-term storage.

What controls should be included when using SOX4 antibodies?

Rigorous experimental design requires appropriate controls to validate SOX4 antibody specificity and performance in each application. Positive controls should include tissues or cell lines known to express SOX4, such as SH-SY5Y neuroblastoma cells or subsets of cells in the granule cell layer of the hippocampal dentate gyrus, which have demonstrated reliable SOX4 immunoreactivity in previous studies . Negative controls should include tissues lacking SOX4 expression or comparison with isotype control antibodies that match the SOX4 antibody's class and species but lack specific binding capacity. For definitive validation, tissues or cells from SOX4 knockout models provide the gold standard negative control, similar to the approach used for evaluating SNTA antibodies where tissues from deficient animals were employed . When examining SOX4 expression patterns, researchers should remain aware of potential cross-reactivity with other SOX family members due to conserved sequence homology, particularly in the DNA-binding HMG box domain, making thorough validation with appropriate controls essential for accurate interpretation of experimental results.

How do different SOX4 antibody clones compare in performance?

Different SOX4 antibody clones demonstrate variable performance characteristics that should inform selection for specific experimental applications. The CL5634 clone (NBP2-61420) has been extensively validated for immunocytochemistry and immunohistochemistry applications, showing strong nuclear staining in both cell culture and tissue sections with minimal background . This antibody has demonstrated particularly strong nuclear immunoreactivity in subsets of cells in the dentate gyrus granule cell layer and in human glioma samples, making it particularly valuable for neuro-oncology research . By comparison, the B-7 clone (sc-518016) provides broader application flexibility with validated protocols for Western blotting, immunoprecipitation, immunofluorescence, and ELISA techniques across mouse, rat, and human samples . When selecting between antibody clones, researchers should consider not only the validated applications but also the specific epitope recognition, as different clones may target distinct regions of the SOX4 protein, potentially affecting detection in experimental conditions where protein conformation, post-translational modifications, or protein-protein interactions may mask certain epitopes. Performance comparison studies between different clones in the same experimental system are highly recommended before committing to large-scale studies.

What are the technical challenges in developing highly specific antibodies?

The development of highly specific antibodies presents significant technical challenges that researchers must understand when interpreting experimental results. As demonstrated in studies developing antibodies against botulinum neurotoxin epitopes, achieving high specificity requires sophisticated immunization strategies and screening methods . For neoepitope-specific antibodies like those detecting cleaved SNAP-25, researchers found that conventional immunization in mice often produced weak responses that failed to discriminate between cleaved and intact targets, whereas rabbit immunization generated more robust and specific antibody responses . The construction of immune scFv phage-display libraries from immunized animals, followed by stringent selection procedures, has proven effective in isolating antibodies with ultra-high affinity and specificity . When developing antibodies against transcription factors like SOX4, challenges include the high sequence conservation among family members, potential cross-reactivity, and the often low expression levels of these proteins in normal tissues. Sequence analysis of isolated antibody clones from phage display libraries reveals that specificity often correlates with particular features in the complementarity-determining regions (CDRs), with studies showing that exceptionally short HCDR3 sequences can sometimes provide superior specificity for certain epitopes .

How can researchers validate SOX4 antibody specificity for their experimental system?

Rigorous validation of SOX4 antibody specificity requires a multi-faceted approach tailored to the experimental system being employed. Western blot analysis represents a crucial validation method, where antibodies should detect a single band at the expected molecular weight of SOX4 (approximately 47 kDa) in positive control samples while showing no reactivity in negative controls . For definitive validation, genetic approaches using SOX4 knockout or knockdown systems provide the gold standard, analogous to the approach used for SNTA antibodies where tissues from deficient animals demonstrated complete absence of signal . When knockout models are unavailable, peptide competition assays can provide evidence for specificity, wherein pre-incubation of the antibody with excess immunizing peptide should abolish specific staining in subsequent applications. Researchers should also perform cross-reactivity testing against other SOX family members, particularly SOX11 and SOX12 which share significant sequence homology with SOX4. For immunohistochemistry and immunofluorescence applications, pattern validation is essential, with SOX4 expected to show predominantly nuclear localization consistent with its function as a transcription factor . Multiple antibody validation, using different antibodies targeting distinct epitopes of SOX4, provides additional confidence in the specificity of observed signals when staining patterns coincide.

What are the considerations for using SOX4 antibodies in different tissue types?

SOX4 expression patterns and detectability vary significantly across tissue types, requiring careful optimization of antibody protocols for each experimental context. In neural tissues, SOX4 demonstrates strong nuclear immunoreactivity in specific subpopulations, such as a subset of cells in the granule cell layer of the hippocampal dentate gyrus, requiring careful consideration of anatomical specificity when interpreting results . For oncology research, SOX4 antibodies have shown moderate to strong nuclear positivity in human glioma tumor cells, making them valuable tools for investigating SOX4's role in cancer biology . When working with formalin-fixed, paraffin-embedded (FFPE) tissues, antigen retrieval methods significantly impact detection sensitivity, with heat-induced epitope retrieval at pH 6.0 typically yielding optimal results for SOX4 antibodies . The tissue fixation method substantively affects antibody performance, with paraformaldehyde fixation followed by Triton X-100 permeabilization commonly recommended for immunofluorescence applications to preserve epitope accessibility while maintaining cellular architecture . Researchers should be aware that SOX4 expression levels vary dynamically during development and in different physiological states, necessitating appropriate developmental stage-matched controls when studying embryonic or developmental processes.

What are the recommended protocols for using SOX4 antibodies in immunohistochemistry?

Successful immunohistochemical detection of SOX4 requires careful optimization of multiple protocol parameters. For formalin-fixed, paraffin-embedded tissue sections, a recommended protocol begins with deparaffinization followed by heat-induced epitope retrieval (HIER) at pH 6.0, which has been established as optimal for SOX4 antibody access to nuclear epitopes . Following antigen retrieval, sections should be blocked with appropriate serum (typically 5-10% normal serum from the same species as the secondary antibody) to reduce non-specific binding. Primary SOX4 antibody incubation should be performed at dilutions between 1:1000 and 1:2500, with overnight incubation at 4°C typically yielding optimal signal-to-noise ratios . For detection systems, both chromogenic methods using horseradish peroxidase and 3,3'-diaminobenzidine (DAB) or fluorescent secondary antibodies can be employed depending on the experimental requirements. When analyzing results, researchers should focus on nuclear staining patterns, as cytoplasmic signals may represent nonspecific binding or background. For multiplexed studies examining SOX4 alongside other markers, careful consideration of antibody species and detection systems is necessary to prevent cross-reactivity, with sequential staining protocols often preferred for markers requiring the same species of primary antibody.

How can SOX4 antibodies be effectively used in Western blotting?

Optimal Western blot protocols for SOX4 detection require careful consideration of sample preparation, protein separation, and detection parameters. SOX4 is predominantly located in the nucleus, necessitating efficient nuclear protein extraction methods that typically employ detergent-based lysis buffers containing protease inhibitors to prevent degradation during sample processing . Since SOX4 has a molecular weight of approximately 47 kDa, 10% polyacrylamide gels provide suitable resolution, with careful attention to loading controls that reflect nuclear protein content rather than cytoplasmic housekeeping proteins . For membrane transfer, nitrocellulose membranes with 0.45 μm pore size have been successfully used for SOX4 detection, though PVDF membranes may provide higher protein binding capacity for low abundance samples . Blocking with 1-5% non-fat dry milk or bovine serum albumin in TBS-T (Tris-buffered saline with 0.1% Tween-20) helps reduce background while preserving antibody access to specific epitopes. Primary SOX4 antibody incubation typically requires optimization but often performs well at dilutions around 1:1000 when using concentrated (200 μg/ml) stock solutions . Detection systems can include HRP-conjugated secondary antibodies with enhanced chemiluminescence or fluorescently labeled secondary antibodies for multiplex detection platforms like the Odyssey system, with the latter offering advantages for quantitative analysis .

What methodology should be followed for SOX4 immunoprecipitation experiments?

Immunoprecipitation (IP) of SOX4 requires specialized protocols to efficiently isolate this nuclear transcription factor while maintaining protein-protein interactions of interest. When planning SOX4 IP experiments, researchers should begin with optimized nuclear extraction protocols that balance efficient solubilization with preservation of protein complexes, typically employing buffers containing 0.1% non-ionic detergents like Triton X-100 or NP-40 . Pre-clearing of nuclear lysates with protein A/G beads helps reduce non-specific binding before adding the SOX4 antibody. For the immunoprecipitation step itself, antibodies specifically validated for IP applications, such as the B-7 clone (sc-518016), should be used at manufacturer-recommended concentrations, typically requiring 2-5 μg of antibody per 500 μg of nuclear extract . The antibody-protein complex can be captured using either agarose-conjugated secondary antibodies or protein A/G beads, with the former potentially offering advantages for reduced background. Wash conditions represent a critical parameter requiring optimization, with stringency balanced against preservation of specific interactions through careful buffer composition. For subsequent analysis of SOX4 binding partners, mass spectrometry-based approaches provide unbiased identification, while targeted Western blotting can confirm specific interactions with suspected binding partners. Controls should include IP with isotype-matched control antibodies and, when possible, experimental conditions where SOX4 expression is knocked down to identify non-specific binding.

What are the best practices for quantifying SOX4 using immunofluorescence techniques?

Accurate quantification of SOX4 expression by immunofluorescence requires rigorous methodological approaches and appropriate image analysis techniques. Standardized sample preparation is essential, with consistent fixation (typically 4% paraformaldehyde) and permeabilization (0.1-0.3% Triton X-100) protocols across all experimental groups . When staining cultured cells like SH-SY5Y, which show specific SOX4 nuclear localization, optimal antibody concentrations typically range from 2-10 μg/ml, with titration experiments recommended to determine the ideal concentration that maximizes specific signal while minimizing background . Multi-channel imaging should include nuclear counterstains (such as DAPI or Hoechst) to define nuclear regions for quantification, cytoskeletal markers (like tubulin) to delineate cell boundaries, and the SOX4 signal itself, enabling accurate segmentation during image analysis . For quantitative analysis, confocal microscopy with standardized acquisition parameters (laser power, detector gain, pinhole size) across all samples is strongly recommended to ensure comparable signal intensity measurements. Image analysis should employ nuclear segmentation based on the DNA counterstain, followed by measurement of SOX4 signal intensity within these nuclear regions, with careful background subtraction procedures. Relative quantification approaches using internal controls and normalization to total nuclear area or intensity can help account for variations in cell density and imaging conditions across samples.

How can researchers address weak or absent SOX4 staining?

When confronted with weak or absent SOX4 staining, researchers should systematically evaluate and optimize multiple experimental parameters. Insufficient antigen retrieval represents a common cause of weak nuclear staining in formalin-fixed tissues, which can be addressed by extending heat-induced epitope retrieval times or adjusting buffer pH, with pH 6.0 citrate buffer typically yielding optimal results for SOX4 detection . Antibody concentration should be titrated using positive control tissues known to express SOX4, such as specific regions of the hippocampus or certain cancer cell lines, with starting dilutions of 1:1000-1:2500 for immunohistochemistry and 2-10 μg/ml for immunofluorescence applications . Fixation protocols significantly impact epitope preservation and accessibility, with overfixation potentially masking SOX4 epitopes; researchers might consider reduced fixation times or alternative fixatives if standard protocols yield poor results. The age of tissue samples and storage conditions can affect antigenicity, with fresher samples typically providing stronger signals. For immunofluorescence applications, signal amplification systems such as tyramide signal amplification (TSA) or higher sensitivity detection systems may help visualize low abundance SOX4 expression. Finally, researchers should verify they are examining appropriate anatomical regions, as SOX4 expression is highly tissue-specific, with strong nuclear immunoreactivity limited to certain cell populations such as subsets of cells in the dentate gyrus granule cell layer .

What strategies can resolve high background issues when using SOX4 antibodies?

High background represents a common challenge when working with nuclear antigens like SOX4, requiring systematic optimization approaches to improve signal-to-noise ratios. Increasing blocking stringency by using higher concentrations (5-10%) of serum or bovine serum albumin and extending blocking times (1-2 hours at room temperature) can effectively reduce non-specific antibody binding . For tissue sections showing high background, additional blocking steps with avidin/biotin blocking kits may be beneficial if biotinylated secondary detection systems are employed. Optimizing antibody dilutions is critical, as excessively concentrated primary antibody solutions often contribute to high background; careful titration experiments starting from manufacturer recommendations (typically 1:1000-1:2500 for immunohistochemistry) help identify the optimal concentration that maximizes specific signal while minimizing background . Wash steps should be extended and performed with gentle agitation using buffers containing 0.1-0.3% Tween-20 or Triton X-100 to remove unbound antibodies more effectively. For fluorescence applications, autofluorescence can be reduced through pretreatment with sodium borohydride or specialized quenching reagents, particularly important for tissues like brain that contain lipofuscin. When high background persists, switching to more specific detection systems, such as tyramide signal amplification or directly conjugated primary antibodies, may improve signal-to-noise ratios by eliminating potential cross-reactivity from secondary antibodies.

How can cross-reactivity with other SOX family proteins be identified and minimized?

Cross-reactivity with other SOX family members represents a significant concern when using SOX4 antibodies due to the high sequence homology within this protein family. To identify potential cross-reactivity, researchers should first examine antibody epitope information, with antibodies targeting the more variable C-terminal or N-terminal regions typically offering greater specificity than those recognizing the highly conserved HMG-box DNA-binding domain . Testing the antibody against recombinant SOX family proteins by Western blot can provide direct evidence of cross-reactivity, with particular attention to SOX11 and SOX12, which share the highest sequence similarity with SOX4. For definitive assessment in experimental systems, parallel knockdown experiments using siRNA or shRNA specifically targeting SOX4 should eliminate true SOX4 signals while leaving cross-reactive signals intact. Pre-absorption controls, where the antibody is pre-incubated with excess SOX4 recombinant protein or immunizing peptide before application to samples, can help distinguish specific from non-specific binding. To minimize cross-reactivity in experimental applications, researchers should select antibodies specifically validated for minimal cross-reactivity with other SOX family members, optimize antibody dilutions to favor high-affinity specific binding over lower-affinity cross-reactive binding, and consider using orthogonal detection methods like RNA-scope or PCR to confirm protein expression patterns with transcript localization.

What approaches can improve reproducibility in SOX4 antibody-based experiments?

Ensuring reproducibility in SOX4 antibody-based experiments requires meticulous attention to multiple methodological factors across experimental workflows. Comprehensive antibody validation represents the foundation of reproducible experiments, with researchers strongly advised to independently verify commercial antibody performance in their specific experimental systems using positive and negative controls . Detailed documentation of antibody characteristics including clone number, lot number, concentration, and supplier information should be maintained and reported in publications to facilitate replication . Standardization of sample preparation protocols, including consistent fixation methods and times, is critical as variations can significantly alter epitope accessibility and detection sensitivity . For quantitative applications, implementing calibration standards or reference samples across experimental batches helps normalize for day-to-day variations in staining intensity or instrument performance. Image acquisition parameters, including exposure times, gain settings, and threshold values, should be standardized and reported to ensure comparable data collection across experiments. Blinded analysis by multiple observers using pre-established scoring criteria can reduce unconscious bias in interpreting SOX4 expression patterns. For long-term studies, researchers should consider purchasing sufficient antibody from a single lot to complete the entire study, as lot-to-lot variations can introduce significant variability in antibody performance despite identical catalog numbers . Finally, implementing positive and negative controls in every experimental run provides critical internal validation and helps identify potential technical issues affecting reproducibility.

How are advanced antibody engineering techniques improving SOX4 antibody specificity?

Recent advances in antibody engineering are significantly enhancing the specificity and utility of SOX4 antibodies for research applications. Phage display technology has emerged as a powerful approach for generating highly specific antibodies, enabling the selection of clones with exceptional affinity and specificity from large antibody libraries, as demonstrated in studies isolating neoepitope-specific antibodies with picomolar affinity . The construction of immune scFv phage-display libraries from immunized animals, particularly rabbits which often generate more diverse antibody responses than mice, followed by stringent selection procedures has proven particularly effective for isolating antibodies with ultra-high specificity . Sequence analysis of isolated antibody clones has revealed that certain structural features, such as exceptionally short HCDR3 sequences, can sometimes provide superior specificity for certain epitopes, providing valuable insights for antibody engineering . The development of recombinant antibody technologies, including chimeric antibodies combining the variable regions from one species with constant regions from another, has enabled the production of antibodies with optimized properties for specific applications . These engineered antibodies often demonstrate improved stability, reduced background, and enhanced reproducibility compared to traditional monoclonal antibodies. Looking forward, site-specific antibody conjugation methods are enabling the precise addition of fluorophores or other detection moieties at positions that don't interfere with antigen binding, potentially improving signal-to-noise ratios in SOX4 detection applications.

What are emerging applications of SOX4 antibodies in cancer research?

SOX4 antibodies are playing an increasingly important role in cancer research, with several emerging applications revealing new insights into tumor biology. Immunohistochemical studies using SOX4 antibodies have demonstrated that SOX4 expression is upregulated in various cancer types, with staining of human glioma samples showing moderate to strong nuclear positivity in tumor cells, suggesting potential roles in oncogenesis . Beyond simple expression analysis, SOX4 antibodies are being employed in chromatin immunoprecipitation sequencing (ChIP-seq) studies to identify genome-wide binding sites of SOX4 in cancer cells, revealing its direct transcriptional targets and regulatory networks that contribute to malignant phenotypes. Multiplexed immunofluorescence approaches combining SOX4 antibodies with markers of cancer stem cells are helping to elucidate the role of SOX4 in maintaining tumor-initiating cell populations that drive cancer progression and therapeutic resistance. In translational research, SOX4 expression patterns detected by immunohistochemistry are being evaluated as potential prognostic biomarkers, with preliminary studies suggesting correlations between SOX4 expression levels and clinical outcomes in certain cancer types. Novel proximity ligation assays utilizing SOX4 antibodies are enabling the visualization and quantification of protein-protein interactions involving SOX4 in situ within tumor tissues, providing insights into the molecular mechanisms through which SOX4 contributes to oncogenic signaling pathways.

How can researchers implement multiplex detection systems with SOX4 antibodies?

Implementing multiplex detection systems with SOX4 antibodies requires careful consideration of antibody compatibility and detection strategy selection. Sequential immunostaining protocols represent one approach for multiplexing, wherein complete staining with one antibody (including detection and signal development) is performed before beginning the staining process with the next antibody, often with an intervening antibody stripping or blocking step to prevent cross-reactivity . When designing multiplex panels including SOX4, researchers should carefully select antibodies raised in different host species to enable simultaneous staining with species-specific secondary antibodies conjugated to spectrally distinct fluorophores. The nuclear localization of SOX4 provides a natural spatial separation from many cytoplasmic or membrane markers, facilitating clear discrimination in multiplexed images . Advanced multiplexing approaches such as tyramide signal amplification (TSA) can allow the use of multiple primary antibodies from the same host species by employing sequential TSA labeling with intervening antibody stripping steps. Mass cytometry or imaging mass cytometry using metal-conjugated SOX4 antibodies enables highly multiplexed analyses with dozens of simultaneous markers, though these techniques require specialized equipment. For quantitative multiplex analysis, careful optimization of antibody concentrations is essential, as certain antibodies may require different dilutions in multiplex settings compared to single-plex applications due to potential interference between detection systems. Automated multispectral imaging platforms combined with artificial intelligence-based image analysis algorithms are increasingly being utilized to objectively quantify SOX4 expression in the context of complex tissue microenvironments with multiple markers.